Infliximab Biosimilar Initiation Has Increased in Pediatric IBD, Study Finds
Pharmacy Times
JULY 8, 2025
Further research is needed on the clinical impact, treatment longevity, and cost implications of biosimilar use in pediatric IBD. These diseases are caused by a dysregulated mucosal immune response to the intestinal microflora in hosts who are genetically predisposed.
Let's personalize your content